- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days of rumors, is a story of second acts. It represents a new chance for a type of
cholesterol-lowering drug that was once predicted to generate many billions of dollars in annual sales, but has so far disappointed drug makers and investors, to dominate the landscape for
heart medicines. It’s also a triumphant final act for Clive Meanwell, who founded The Medicines Company in 1996 and ran it through a quarter-century roller-coaster ride that saw the firm
become a Wall Street darling, fall from favor, and, in the past year, reach new highs. And it’s a second act for The Medicines Company’s current CEO, who previously spent almost four years
as the chief executive of Purdue Pharma, the company whose name has become synonymous with the opioid epidemic. The deal also represents another victory for Alexander Denner of Sarissa
Capital, who took control of The Medicines Company’s board last March and is chairman of the company’s board of directors. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE
IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans
Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe
